Activation of the Zymogen to Urokinase-Type Plasminogen Activator Is Associated with Increased Interdomain Flexibility

被引:9
|
作者
Behrens, Manja A. [2 ,3 ]
Botkjaer, Kenneth A. [1 ,4 ]
Goswami, Sumit [5 ]
Oliveira, Cristiano L. P. [2 ,3 ]
Jensen, Jan K. [1 ,4 ]
Schar, Christine R. [1 ]
Declerck, Paul J. [5 ]
Peterson, Cynthia B. [6 ]
Andreasen, Peter A. [1 ,4 ]
Pedersen, Jan Skov [2 ,3 ]
机构
[1] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark
[2] Aarhus Univ, Dept Chem, DK-8000 Aarhus C, Denmark
[3] Aarhus Univ, iNANO Interdisciplinary Nanosci Ctr, DK-8000 Aarhus C, Denmark
[4] Danish Chinese Ctr Proteases & Canc, Aarhus, Denmark
[5] Katholieke Univ Leuven, Dept Pharmaceut Sci, B-3000 Louvain, Belgium
[6] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA
基金
新加坡国家研究基金会;
关键词
small-angle X-ray scattering; serine protease; analytical ultracentrifugation; kringle; epidermal growth factor; PROTEIN UROKINASE; DOMAIN-STRUCTURE; STRUCTURAL BASIS; SCATTERING; SITE; MACROMOLECULES; INITIATION; RECEPTORS; MECHANISM; DYNAMICS;
D O I
10.1016/j.jmb.2011.05.026
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A key regulatory step for serine proteases of the trypsin clan is activation of the initially secreted zymogens, leading to an increase in activity by orders of magnitude. Zymogen activation occurs by cleavage of a single peptide bond near the N-terminus of the catalytic domain. Besides the catalytic domain, most serine proteases have N-terminal A-chains with independently folded domains. Little is known about how zymogen activation affects the interplay between domains. This question is investigated with urokinase-type plasminogen activator (uPA), which has an epidermal growth factor domain and a kringle domain, connected to the catalytic domain by a 15-residue linker. uPA has been implicated under several pathological conditions, and one possibility for pharmacological control is targeting the conversion of the zymogen pro-uPA to active uPA. Therefore, a small-angle X-ray scattering study of the conformations of pro-uPA and uPA in solution was performed. Structural models for the proteins were derived using available atomic-resolution structures for the various domains. Active uPA was found to be flexible with a random conformation of the amino-terminal fragment domain with respect to the serine protease domain. In contrast, pro-uPA was observed to be rigid, with the amino-terminal fragment domain in a fixed position with respect to the serine protease domain. Analytical ultracentrifugation analysis supported the observed difference between pro-uPA and uPA in overall shape and size seen with small-angle X-ray scattering. Upon association of either of two monoclonal Fab (fragment antigen-binding) fragments that are directed against the catalytic domain of, respectively, pro-uPA and uPA, rigid structures were formed. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:417 / 429
页数:13
相关论文
共 50 条
  • [41] Role of urokinase-type plasminogen activator in local immunotherapy
    Takeda, T
    Ito, Y
    Wakasugi, E
    Kobayashi, T
    Monden, M
    ONCOLOGY REPORTS, 1998, 5 (02) : 329 - 333
  • [42] The urokinase-type plasminogen activator and its receptor in cancer
    Rosenberg, S
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 121 - 128
  • [43] THE MURINE UROKINASE-TYPE PLASMINOGEN-ACTIVATOR GENE
    DEGEN, SJF
    HECKEL, JL
    REICH, E
    DEGEN, JL
    BIOCHEMISTRY, 1987, 26 (25) : 8270 - 8279
  • [44] Inhibitors of the protease domain of urokinase-type plasminogen activator
    Rockway, TW
    Nienaber, V
    Giranda, VL
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (28) : 2541 - 2558
  • [45] Association of urokinase-type plasminogen activator with asthma and atopy
    Begin, Philippe
    Tremblay, Karine
    Daley, Denise
    Lemire, Mathieu
    Claveau, Sebastien
    Salesse, Charleen
    Kacel, Sabine
    Montpetit, Alexandre
    Becker, Allan
    Chan-Yeung, Moira
    Kozyrskyj, Anita L.
    Hudson, Thomas J.
    Laprise, Catherine
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2007, 175 (11) : 1109 - 1116
  • [46] ACTIVATION WITH PLASMIN OF 2-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR DERIVED FROM SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY TREATMENT WITH THROMBIN
    LIJNEN, HR
    VANHOEF, B
    COLLEN, D
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1987, 169 (02): : 359 - 364
  • [47] The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
    Carriero, Maria Vincenza
    Stoppelli, Maria Patrizia
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (19) : 1944 - 1961
  • [48] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR RECEPTOR AND PLASMINOGEN-ACTIVATOR INHIBITOR-1 I IN BREAST-CANCER CELLS
    WAJIMA, T
    DEGEN, D
    ORIZ, V
    VONHOFFOLIN, DD
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 1284 - 1284
  • [49] Characterization of the murine plasminogen/urokinase-type plasminogen-activator system
    Lijnen, HR
    VanHoff, B
    Collen, D
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 241 (03): : 840 - 848
  • [50] In-vivo imaging of tumor associated urokinase-type plasminogen activator activity
    Hsiao, Jong-Kai
    Law, Benedict
    Weissleder, Ralph
    Tung, Ching-Hsuan
    JOURNAL OF BIOMEDICAL OPTICS, 2006, 11 (03)